Conclusion: In addition to inducing p75NTR up-regulation, inflammatory stimuli increase the release of proNGF in arthritis SFs. Autocrine proNGF binds to p75NTR and further enhances pro-inflammatory cytokine production, creating a vicious circle that amplifies the inflammatory response. Blocking the binding of endogenous proNGF to its receptor p75NTR strongly reduces the production of inflammatory mediators and prospects the use of p75NTR inhibitors as a new therapeutic approach to chronic arthritis.

REFERENCES

Disclosure of Interests: Patrick Schopohl: None declared, Suchi Smita: None declared, Faiz Khan: None declared, Tom Gebhardt: None declared, Math Hoch: None declared, David Brauer: None declared, Konstanin Cesnulevicius: Employee of: Biologische Heilmittel Heel GmbH, Myron Schultz: Employee of: Biologische Heilmittel Heel GmbH, Olaf Wolkenhauer: Research support from: The research project was financially supported by Biologische Heilmittel Heel GmbH (Heel), Consultant for: I have received consultancy honoraria from Heel, Shailendra Gupta: Research support from: The research project was financially supported by Biologische Heilmittel Heel GmbH (Heel), Consultant for: I have received consultancy honoraria from Heel

SERUM TENASCIN-C LEVELS ARE ELEVATED IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS

Hana Hulejova,1 Kristyna Bubova,2 Klara Prazlerova,2 Marketa Husakova,2 Maria Filkova,2 Michal Tomlik,2 Karel Pavelka,2 Ladislav Senolt,2 1Institute of Rheumatology, Prague, Czech Republic; 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

Background: Tenascin-C (TNC) is a pro-inflammatory extracellular matrix glycoprotein that is synthesized in various pathological conditions. TNC induces inflammatory activity and promotes damage of joints. Its expression in adults is restricted to sites of tissue injury, particularly during phases of inflammation and active tissue remodelling. Only a few studies have described elevated serum TNC levels in ankylosing spondylitis (AS) compared to healthy controls (HC).

Objectives: The aim of this study was to examine the levels of serum TNC among different axial spondyloarthritides (axSpA) subsets and whether TNC levels are related to disease activity measures or other clinical features.

Methods: Sixty-one patients who fulfilled the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA and twenty age and sex-matched HC were included in this study. Based on imaging, patients were further classified as AS (n = 45) and as nr-axSpA (n = 16). Patients with AS were further divided into two subsets based on the absence (n=22) or presence of syndesmophytes (n=23).

TNC serum levels were determined using ELISA. The following data were collected: clinical and laboratory disease activity measures; demographic status; disease-related factors such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and CRP levels. Statistical analyses were performed with GraphPad Prism 5.1. The data are presented as the median and interquartile range.

Results: TNC serum levels were elevated in axSpA patients (535.3 (457.7-677.2) ng/mL) compared to HC (432.1 (329.1-565.9) ng/mL, p = 0.007). Dividing TNC serum levels were elevated in axSpA patients (535.3 (457.7-677.2) ng/mL) compared to HC (432.1 (329.1-565.9) ng/mL, p = 0.007).

Conclusion: We demonstrated here elevated serum TNC levels in patients with axSpA, particularly in those with syndesmophytes, which may suggest its role in bone formation during radiographic stage of the disease.

Acknowledgement: This work was supported by MH CR 032728, SVV 260373, AVZ - 17-33127A

Disclosure of Interests: Hana Hulejova: None declared, Kristyna Bubova: None declared, Klara Prazlerova: None declared, Marketa Husakova: None declared, Maria Filkova: None declared, Michal Tomlik: None declared, Karel Pavelka: None declared, Ladislav Senolt Grant/research support from: AbbVie, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene Corporation, Merck Sharp and Dohme, Novartis, Pfizer, Roche, UCb, Amgen, Takeda, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Merck Sharp and Dohme, Novartis, Pfizer, Roche, UCb